Received May 30, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y000225 | OT |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y017208 | OT |
no additional AE; a 31 year old patient was administered both PROQUAD and VARIVAX on 4/16/2025.; PROQUAD was given to a 31-year-old patient; A dose of VARIVAX was given previously on 3/17/2025 and a dose of PROQUAD was given on 3/21/2025 to the same patient.; This spontaneous report was received from a nurse on 27-May-2025 and refers to a 31-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 17-Mar-2025, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX REFRIGERATOR STABLE), (lot #Y014939, expiration date: 04-Sep-2026) 0.5 ml, administered by Intramuscular route. On 21-Mar-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y000225, expiration date: 03-Jan-2026) 0.5 mL, administered by Intramuscular route (Product administered to patient of inappropriate age, Inappropriate schedule of product administration). On 16-Apr-2025, the patient was vaccinated with Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX REFRIGERATOR STABLE), (lot #Y014939, expiration date: 04-Sep-2026) 0.5 ml, administered by Intramuscular route and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), (lot #Y017208, expiration date: 13-Apr-2026) 0.5 mL, administered by Intramuscular route (overdose). The vaccines were reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot # and expiration date unknown). The vaccines were administered as prophylaxis. No additional AE (no adverse event).
Sterile diluent